Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Firm Signs Paid Pilot Agreements to Test Telemedicine Platform in 5 States
News Update

Share on Stocktwits


With this development, the Canadian company further expands its U.S. footprint.

Reliq Health Technologies Inc. (RHT:TSX.V; RQHTF:OTCQB) signed agreements with five new clients in five states to conduct 30- to 90-day, paid pilot trials of its iUGO Care platform, the company announced in a news release.

Reliq's system allows for remote telemedicine delivery, patient monitoring and chronic disease control. The entities testing it are a sizable employer health plan, a statewide health system's home health services division, a pulmonary medicine center, a home health agency serving 11 counties and a health system encompassing an acute care hospital and multiple senior living communities. The pilot organizations are located in Florida, Maryland, New Jersey, Montana and Illinois.

"These pilots will use iUGO Care to improve health outcomes and reduce the cost of care for patients with a broad range of clinical conditions, including chronic obstructive pulmonary disease, sleep apnea, chronic wounds, diabetes, hypertension and congestive heart failure," said Reliq CEO Dr. Lisa Crossley in the release.

The pilot programs will start in Q2/19. As each company goes live with iUGO Care, it will issue a joint press release with Reliq.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Reliq Health Technologies, a company mentioned in this article.

Want to read more about Life Sciences Tools & Diagnostics investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe